MIRM - Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU

• A committee of the European Medicines Agency (EMA) recommended granting marketing authorization under exceptional circumstances to Mirum Pharmaceuticals' ( NASDAQ: MIRM ) Livmarli to treat cholestatic pruritus (itching) in patients two  months of age and older with Alagille syndrome (ALGS).
• ALGS is a rare genetic disorder whichcan affect multiple organs, but mainly liver. In the condition, bile builds up in the liver because there are few bile ducts to drain the bile.
• Livmarli will be available as an oral solution, the The EMA's Committee for Medicinal Products for Human Use (CHMP) said on Friday.
• The European Commission, which generally follows the opinion of the CHMP, will now decide on the drug's approval.
• Livmarli was approved in the U.S. in September 2021.

For further details see: